Alnylam Pharmaceuticals (ALNY) to Release Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is projected to post its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Alnylam Pharmaceuticals to post earnings of $1.43 per share and revenue of $1.1574 billion for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:30 AM ET.

Alnylam Pharmaceuticals Stock Down 2.5%

ALNY stock opened at $320.00 on Tuesday. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. The company has a market capitalization of $42.28 billion, a price-to-earnings ratio of 1,333.33 and a beta of 0.35. Alnylam Pharmaceuticals has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The stock has a fifty day moving average of $386.86 and a 200-day moving average of $425.68.

Insider Activity at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,650 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $453.69, for a total value of $7,100,248.50. Following the transaction, the chief executive officer owned 65,409 shares of the company’s stock, valued at $29,675,409.21. This represents a 19.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Pushkal Garg sold 1,510 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70. Following the sale, the executive vice president owned 22,511 shares in the company, valued at approximately $8,168,566.57. This trade represents a 6.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 56,955 shares of company stock valued at $24,072,733 in the last ninety days. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $243,000. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Alnylam Pharmaceuticals by 14.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 567 shares of the biopharmaceutical company’s stock valued at $259,000 after acquiring an additional 71 shares during the last quarter. Glenmede Investment Management LP purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at about $221,000. Quadrant Capital Group LLC purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at about $252,000. Finally, ICONIQ Capital LLC bought a new position in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $263,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of research reports. JPMorgan Chase & Co. cut their target price on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research report on Monday, October 13th. Truist Financial dropped their price target on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Raymond James Financial reiterated an “outperform” rating and issued a $472.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. Wells Fargo & Company cut their price target on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a report on Tuesday, January 20th. Finally, Royal Bank Of Canada decreased their price objective on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 20th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $477.13.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.